Literature DB >> 22370340

N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation.

Aleem Gangjee1, Nilesh Zaware, Sudhir Raghavan, Jie Yang, Jessica E Thorpe, Michael A Ihnat.   

Abstract

With the goal of developing multitargeted receptor tyrosine kinase inhibitors that display potent inhibition against PDGFRβ and VEGFR-2 we designed and synthesized eleven N(4)-(3-bromophenyl)-7-(substitutedbenzyl) pyrrolo[2,3-d]pyrimidines 9a-19a. These compounds were obtained from the key intermediate N(4)-(3-bromophenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 29. Various arylmethyl groups were regiospecifically attached at the N7 of 29 via sodium hydride induced alkylation with substituted arylmethyl halides. Compounds 11a and 19a were potent dual inhibitors of PDGFRβ and VEGFR-2. In a COLO-205, in vivo tumor mouse model 11a demonstrated inhibition of tumor growth, metastasis, and tumor angiogenesis that was better than or comparable to the standard compound TSU-68 (SU6668, 8).
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22370340      PMCID: PMC3310894          DOI: 10.1016/j.bmc.2012.01.029

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  37 in total

1.  High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications.

Authors:  B R Stockwell; S J Haggarty; S L Schreiber
Journal:  Chem Biol       Date:  1999-02

Review 2.  The discovery of receptor tyrosine kinases: targets for cancer therapy.

Authors:  Andreas Gschwind; Oliver M Fischer; Axel Ullrich
Journal:  Nat Rev Cancer       Date:  2004-05       Impact factor: 60.716

3.  4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.

Authors:  P M Traxler; P Furet; H Mett; E Buchdunger; T Meyer; N Lydon
Journal:  J Med Chem       Date:  1996-06-07       Impact factor: 7.446

4.  An activity-based probe for the determination of cysteine cathepsin protease activities in whole cells.

Authors:  Jean-Pierre Falgueyret; W Cameron Black; Wanda Cromlish; Sylvie Desmarais; Sonia Lamontagne; Christophe Mellon; Denis Riendeau; Sevgi Rodan; Paul Tawa; Gregg Wesolowski; Kathryn E Bass; Shankar Venkatraman; M David Percival
Journal:  Anal Biochem       Date:  2004-12-15       Impact factor: 3.365

5.  SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

Authors:  T A Fong; L K Shawver; L Sun; C Tang; H App; T J Powell; Y H Kim; R Schreck; X Wang; W Risau; A Ullrich; K P Hirth; G McMahon
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

6.  A fast flexible docking method using an incremental construction algorithm.

Authors:  M Rarey; B Kramer; T Lengauer; G Klebe
Journal:  J Mol Biol       Date:  1996-08-23       Impact factor: 5.469

7.  Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors.

Authors:  Yasushi Miyazaki; Shinichiro Matsunaga; Jun Tang; Yutaka Maeda; Masato Nakano; Rocher J Philippe; Megumi Shibahara; Wei Liu; Hideyuki Sato; Liping Wang; Robert T Nolte
Journal:  Bioorg Med Chem Lett       Date:  2005-05-02       Impact factor: 2.823

Review 8.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.

Authors:  Daniel J Hicklin; Lee M Ellis
Journal:  J Clin Oncol       Date:  2004-12-07       Impact factor: 44.544

9.  Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.

Authors:  Ralf Erber; Andreas Thurnher; Alice D Katsen; Gesine Groth; Heinz Kerger; Hans-Peter Hammes; Michael D Menger; Axel Ullrich; Peter Vajkoczy
Journal:  FASEB J       Date:  2003-12-04       Impact factor: 5.191

10.  Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression.

Authors:  L Holmgren; M S O'Reilly; J Folkman
Journal:  Nat Med       Date:  1995-02       Impact factor: 53.440

View more
  3 in total

1.  Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.

Authors:  Roheeth Kumar Pavana; Shruti Choudhary; Anja Bastian; Michael A Ihnat; Ruoli Bai; Ernest Hamel; Aleem Gangjee
Journal:  Bioorg Med Chem       Date:  2016-11-15       Impact factor: 3.641

2.  Discovery of antitubulin agents with antiangiogenic activity as single entities with multitarget chemotherapy potential.

Authors:  Aleem Gangjee; Roheeth Kumar Pavana; Michael A Ihnat; Jessica E Thorpe; Bryan C Disch; Anja Bastian; Lora C Bailey-Downs; Ernest Hamel; Rouli Bai
Journal:  ACS Med Chem Lett       Date:  2014-02-27       Impact factor: 4.345

3.  Design, synthesis and biological activity of N4-phenylsubstituted-7H-pyrrolo[2,3-d]pyrimidin-4-amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kinase.

Authors:  Sonali Kurup; Bradley McAllister; Pavlina Liskova; Trusha Mistry; Anthony Fanizza; Dan Stanford; Jolanta Slawska; Ulrich Keller; Alexander Hoellein
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.